Fylnetra Side Effects
Generic name: pegfilgrastim
Medically reviewed by Drugs.com. Last updated on Jun 10, 2023.
Note: This document contains side effect information about pegfilgrastim. Some dosage forms listed on this page may not apply to the brand name Fylnetra.
Applies to pegfilgrastim: subcutaneous solution.
Serious side effects of Fylnetra
Along with its needed effects, pegfilgrastim (the active ingredient contained in Fylnetra) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking pegfilgrastim:
Incidence not known
- Back pain
- black, tarry stools
- bleeding gums
- bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
- bloody or cloudy urine
- blue lips, fingernails, or skin
- chest pain
- decrease or increase in the amount of urine
- difficult or fast breathing
- dry, red, hot, or irritated skin
- fainting or lightheadedness
- fast heartbeat
- feeling of fullness
- fever sores or blisters on the skin
- hives, itching, skin rash
- joint pain, stiffness, or swelling
- lower back or side pain
- painful or difficult urination
- pain spreading to the left shoulder
- pinpoint red spots on the skin
- redness of the skin
- sores, ulcers, or white spots on the lips or in the mouth
- stomach pain
- swelling of the eyelids, face, lips, hands, or feet
- swollen glands
- trouble breathing or swallowing
- unusual bleeding or bruising
- weight gain
Get emergency help immediately if any of the following symptoms of overdose occur while taking pegfilgrastim:
Symptoms of overdose
- Bone pain
- chest pain or tightness
- difficult or labored breathing
Other side effects of Fylnetra
Some side effects of pegfilgrastim may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
- Bone, arm, or leg pain
For Healthcare Professionals
Applies to pegfilgrastim: subcutaneous solution.
The most commonly reported side effects included bone pain, skeletal pain, medullary bone pain, and spontaneously reversible mild to moderate lactate dehydrogenase elevations.[Ref]
Very common (10% or more): Bone pain (up to 31%), skeletal pain (up to 27%), medullary bone pain (up to 26%)
Very common (10% or more): Spontaneously reversible mild to moderate lactate dehydrogenase elevations (up to 18%), spontaneously reversible mild to moderate alkaline phosphatase elevations (up to 11%), spontaneously reversible mild to moderate uric acid elevations (up to 11%)
Common (1% to 10%): Spontaneously reversible severe uric acid elevations
Common (1% to 10%): Fever, non-cardiac chest pain, pain, pyrexia
Uncommon (0.1% to 1%): Asymptomatic splenomegaly, fatal splenic rupture, sickle cell crisis, splenic rupture, splenomegaly/enlarged spleen
Common (1% to 10%): Application site reactions, injection site pain
Uncommon (0.1% to 1%): Injection site erythema, injection site reactions
Postmarketing reports: Application site bruise, application site discomfort, application site hemorrhage, local skin reactions[Ref]
Common (1 to 10%): Diarrhea, nausea
Common (1% to 10%): Chest pain
Uncommon (0.1% to 1%): Capillary leak syndrome, flushing, hypotension
Rare (0.01% to 0.1%): Aortitis
Common (1% to 10%): Headache
Frequency not reported: Dizziness, taste perversion[Ref]
Common (1% to 10%): Periorbital edema[Ref]
Uncommon (0.1% to 1%): Acute respiratory distress syndrome (ARDS), dyspnea, fatal ARDS, interstitial pneumonia, pulmonary adverse reactions, pulmonary edema, pulmonary fibrosis, pulmonary infiltrates, respiratory failure[Ref]
Frequency not reported: Allergies to acrylics
Postmarketing reports: Allergic reactions, allergic-type reactions, anaphylactic reactions[Ref]
Uncommon (0.1% to 1%): Transient elevations in ALT, transient elevations in AST, transient elevations in liver function tests[Ref]
Frequency not reported: Potential for tumor growth stimulatory effects on malignant cells[Ref]
Frequently asked questions
- What are biosimilar drugs?
- What is the difference between Fulphila and Neulasta?
- What is the difference between Udenyca and Neulasta?
- How is Fulphila injected / administered?
- Is Fulphila a chemo drug?
- What does cbqv stand for in pegfilgrastim?
- What is the difference between Udenyca and Fulphila?
- Why do you take Claritin with Neulasta?
- How many biosimilars have been approved in the United States?
More about Fylnetra (pegfilgrastim)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: colony stimulating factors
- En español
- Fylnetra drug information
- Fylnetra (Pegfilgrastim Subcutaneous) (Advanced Reading)
- Fylnetra (Pegfilgrastim-pbbk Subcutaneous) (Advanced Reading)
Related treatment guides
1. Product Information. Neulasta (pegfilgrastim). Amgen. 2002.
2. Cerner Multum, Inc. UK Summary of Product Characteristics.
3. Cerner Multum, Inc. Australian Product Information.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.